GB2333527A - Therapeutic gene - Google Patents

Therapeutic gene

Info

Publication number
GB2333527A
GB2333527A GB9904141A GB9904141A GB2333527A GB 2333527 A GB2333527 A GB 2333527A GB 9904141 A GB9904141 A GB 9904141A GB 9904141 A GB9904141 A GB 9904141A GB 2333527 A GB2333527 A GB 2333527A
Authority
GB
United Kingdom
Prior art keywords
fusion protein
therapeutic gene
polynucleotide sequences
therapeutic genes
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9904141A
Other versions
GB2333527B (en
GB9904141D0 (en
Inventor
Alan John Kingsman
Susan Mary Kingsman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622500.8A external-priority patent/GB9622500D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to GB9904141A priority Critical patent/GB2333527B/en
Publication of GB9904141D0 publication Critical patent/GB9904141D0/en
Publication of GB2333527A publication Critical patent/GB2333527A/en
Application granted granted Critical
Publication of GB2333527B publication Critical patent/GB2333527B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polynucleotide sequences and vectors containing them, for use in gene therapy, the polynucleotide sequences comprising two or more therapeutic genes operably linked to a promoter and encoding a fusion protein product of the therapeutic genes. The fusion protein may be for example a tyrosine hydroxylase (TH)-DOPA decarboxylase (DD) fusion protein in either TH-DD or DD-TH order, useful for treating Parkinson's disease.
GB9904141A 1996-10-29 1997-10-28 Therapeutic gene Expired - Lifetime GB2333527B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9904141A GB2333527B (en) 1996-10-29 1997-10-28 Therapeutic gene

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9622500.8A GB9622500D0 (en) 1996-10-29 1996-10-29 Therapeutic gene
PCT/GB1997/002969 WO1998018934A1 (en) 1996-10-29 1997-10-28 Therapeutic gene
GB9904141A GB2333527B (en) 1996-10-29 1997-10-28 Therapeutic gene

Publications (3)

Publication Number Publication Date
GB9904141D0 GB9904141D0 (en) 1999-04-14
GB2333527A true GB2333527A (en) 1999-07-28
GB2333527B GB2333527B (en) 2001-05-02

Family

ID=26310304

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9904141A Expired - Lifetime GB2333527B (en) 1996-10-29 1997-10-28 Therapeutic gene

Country Status (1)

Country Link
GB (1) GB2333527B (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012109A1 (en) * 1988-06-03 1989-12-14 The United States Of America, As Represented By Th Gene therapy using gene fusions for genetic or acquired disorders
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5344923A (en) * 1992-09-29 1994-09-06 The Ohio State University Research Foundation Nucleotide sequence encoding for bifunctional enzyme for proline production
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
WO1995028493A1 (en) * 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
WO1995034670A2 (en) * 1994-06-06 1995-12-21 Children's Hospital, Inc. Recombinant aav genome encoding immunodeficiency virus protein
WO1996005319A1 (en) * 1994-08-12 1996-02-22 Arch Development Corporation Genetically engineered cells that produce dopamine
WO1996037621A2 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
WO1997018319A1 (en) * 1995-11-14 1997-05-22 Somatix Therapy Corporation Joint expression of gtp cyclohydrolase and tyrosine hydroxylase

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
WO1989012109A1 (en) * 1988-06-03 1989-12-14 The United States Of America, As Represented By Th Gene therapy using gene fusions for genetic or acquired disorders
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
US5344923A (en) * 1992-09-29 1994-09-06 The Ohio State University Research Foundation Nucleotide sequence encoding for bifunctional enzyme for proline production
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
WO1995028493A1 (en) * 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
WO1995034670A2 (en) * 1994-06-06 1995-12-21 Children's Hospital, Inc. Recombinant aav genome encoding immunodeficiency virus protein
WO1996005319A1 (en) * 1994-08-12 1996-02-22 Arch Development Corporation Genetically engineered cells that produce dopamine
WO1996037621A2 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
WO1997018319A1 (en) * 1995-11-14 1997-05-22 Somatix Therapy Corporation Joint expression of gtp cyclohydrolase and tyrosine hydroxylase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROC.NATL.ACAD.SCI. 1993 90 pgs 7889-7893 MARASCO et al. *

Also Published As

Publication number Publication date
GB2333527B (en) 2001-05-02
GB9904141D0 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
DE69434447D1 (en) PLASMIDE FOR GENE THERAPY
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
NZ312332A (en) Recombinational cloning using engineered recombination sites
EP0696206A4 (en) Adenoviruses having modified fiber proteins
CA2257133A1 (en) Human dnase i hyperactive variants
EP1281717A3 (en) Putative ion channel
AU8143894A (en) Mck-10 (mammary carcinoma kinase 10), a receptor tyrosine kinase
EP1044987A3 (en) Gapped 2'-modified oligonucleotides
EP0923293A4 (en) Treatment of diarrhea
EP0861894A4 (en) Differentiation-suppressive polypeptide
IL110284A0 (en) Viral vectors and their use in gene therapy
CA2223433A1 (en) Ob protein compositions and methods
IL109092A (en) Tumor suppressor gene, protein expressed thereby, vectors containing said gene, and use of said vector and protein in cancer treatment
EP0681585A4 (en) Tata-binding protein associated factors, nucleic acids encoding tafs, and methods of use.
WO1996019580A3 (en) Telomerase protein component
OA09116A (en) Novel protein, sequences containing the gene therefore vectors, methods of preparation and use.
EP0770089A4 (en) Growth differentiation factor-12
ZA948987B (en) Therapy
IL111940A (en) Aromatic bicyclic amines
HU9600181D0 (en) The escherichia coli csra gene, protein encoded thereby, and methods of use thereof
PL313445A1 (en) Grb3-3 gene, variants thereof and their use
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
GB2333527A (en) Therapeutic gene
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
AU2390797A (en) Sequences ahead of gene sm22, vectors containing same, and therapeutical uses thereof, particularly for treating vascular diseases

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20171027